Unknown

Dataset Information

0

Antibacterial properties of the CFTR potentiator ivacaftor.


ABSTRACT: Ivacaftor increases CFTR channel activity and improves pulmonary function for individuals bearing a G551D mutation. Because ivacaftor structurally resembles quinolone antibiotics, we tested the hypothesis that ivacaftor possesses antibacterial properties.Bioluminescence, colony forming unit, and minimal inhibitory concentration assays were used to assess viability of Staphylococcus aureus, Pseudomonas aeruginosa and multiple clinical microbial isolates.Ivacaftor induced a dose-dependent reduction in bioluminescence of S. aureus and decreased the number of colony forming units. We observed a similar but less robust effect in P. aeruginosa following outer membrane permeabilization. Ivacaftor inhibited the growth of respiratory isolates of S. aureus and Streptococcus pneumoniae and exhibited positive interactions with antibiotics against lab and respiratory strains of S. aureus and S. pneumoniae.These data indicate that ivacaftor exhibits antibacterial properties and raise the intriguing possibility that ivacaftor might have an antibiotic effect in people with CF.

SUBMITTER: Reznikov LR 

PROVIDER: S-EPMC4718582 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antibacterial properties of the CFTR potentiator ivacaftor.

Reznikov Leah R LR   Abou Alaiwa Mahmoud H MH   Dohrn Cassie L CL   Gansemer Nick D ND   Diekema Daniel J DJ   Stoltz David A DA   Welsh Michael J MJ  

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 20140305 5


<h4>Background</h4>Ivacaftor increases CFTR channel activity and improves pulmonary function for individuals bearing a G551D mutation. Because ivacaftor structurally resembles quinolone antibiotics, we tested the hypothesis that ivacaftor possesses antibacterial properties.<h4>Methods</h4>Bioluminescence, colony forming unit, and minimal inhibitory concentration assays were used to assess viability of Staphylococcus aureus, Pseudomonas aeruginosa and multiple clinical microbial isolates.<h4>Resu  ...[more]

Similar Datasets

| S-EPMC4272825 | biostudies-other
| S-EPMC8703531 | biostudies-literature
| S-EPMC5727471 | biostudies-literature
| S-EPMC8494914 | biostudies-literature
| S-EPMC4390299 | biostudies-literature
| S-EPMC4728415 | biostudies-literature
| S-EPMC10528730 | biostudies-literature
| S-EPMC10079430 | biostudies-literature
| S-EPMC11234710 | biostudies-literature
| S-EPMC5768901 | biostudies-literature